Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Name Policy "Discourages" New Brand Names For Old Ingredients

Executive Summary

FDA's Office of Postmarketing Drug Risk Assessment is "discouraging" applications that would create a new brand name for an existing active ingredient.

You may also be interested in...



Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension

Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra

Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension

Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra

Duloxetine’s Dual Names: Lilly Wants Yentreve As Incontinence Brand

Lilly is asking FDA to accept Yentreve as the trade name for duloxetine for the treatment of stress urinary incontinence

Related Content

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel